RT Journal
A1 Egiziano G, Pilote L, Behlouli H, Daskalopoulou SS
T1 Improved outcomes in heart failure treated with high-dose ace inhibitors and arbs: A population-based study
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2012
FD September 10
VO 172
IS 16
SP 1263
OP 1265
DO 10.1001/archinternmed.2012.2514
UL http://dx.doi.org/10.1001/archinternmed.2012.2514
AB 
Elevated doses of angiotensin II–converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have similarly reduced morbidity and mortality in congestive heart failure (CHF) trials.1- 2 However, despite the recommendations of consensus CHF guidelines to achieve elevated target doses of ACE inhibitors or ARBs,3- 4 patients often receive doses that are lower than those used in large clinical trials, possibly owing to adverse effects.2,5- 6 We conducted a population-based retrospective cohort study to estimate the effect, in real-world clinical practice, of different doses of ACE inhibitors and ARBs on all-cause mortality and CHF readmission in patients with a first CHF admission.